For following the competition: what moved in each program, several studies read as one move.
- Anti-TF/TOP1i Antibody-drug Conjugate XNW28012
- XNW5004
- Subsequent development plans will be determined based on preliminary study results.
- + 2 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Evopoint Biosciences to watchlistEvery Monday by email · turn it off any timePro · free during the beta